Atherosclerosis and Lipoproteins |
From the Department of Laboratory Medicine (T. Miida, K.I., M.O.) and the First Department of Internal Medicine (K.S., K.O., Y.N.), Niigata University School of Medicine, Niigata; the Department of Cardiology, Kido Hospital (T.Y., T.T.), Niigata; the Institute of Medical Science, St. Marianna University School of Medicine (T.K.), Kawasaki; and the Department of Pharmaceutical Care and Clinical Pharmacy (T. Murakami), Tokushima Bunri University, Tokushima, Japan.
Correspondence to Takashi Miida, Department of Laboratory Medicine, Niigata University School of Medicine, Asahimachi 1-757, Niigata, Niigata 951-8510, Japan. E-mail miida{at}med.niigata-u.ac.jp
AbstractPreß1-high density lipoprotein (preß1-HDL), the initial acceptor of cell-derived cholesterol, can be generated from HDL2 by hepatic lipase. Because bezafibrate elevates lipase activity, it may increase preß1-HDL at the expense of HDL2. To answer this question, we determined the apolipoprotein A-I (apoA-I) distribution in 20 hypertriglyceridemics (triglycerides>2.26 mmol/L) and 20 sex-matched normolipidemics by native 2-dimensional gel electrophoresis. At baseline, preß1-HDL was 70% higher in hypertriglyceridemics than in normolipidemics (123.5±49.9 versus 72.5±34.1 mg/L apoA-I, P<0.01). Preß1-HDL was positively correlated with triglyceride (r=0.624, P<0.0001). A 4-week bezafibrate treatment (400 mg daily) increased preß1-HDL by 30% (160.2±64.5 mg/L apoA-I, P<0.05) but decreased HDL2b by 31% (from 188.8±94.9 to 129.3±78.7 mg/L apoA-I, P<0.05). Hepatic lipase activity increased by 24% (P<0.005). Preß1-HDL was generated either from ultracentrifugally isolated HDL2 or from plasma during incubation with triglyceride lipase. In conclusion, bezafibrate increases preß1-HDL at the expense of HDL2. We speculate that such an effect might partly contribute to the antiatherogenic action of bezafibrate.
Key Words: pre-ß-HDL hepatic lipase apolipoprotein A-I LpA-I cholesteryl ester transfer protein
This article has been cited by other articles:
![]() |
S. Hirayama, T. Miida, O. Miyazaki, and Y. Aizawa Pre{beta}1-HDL Concentration Is a Predictor of Carotid Atherosclerosis in Type 2 Diabetic Patients Diabetes Care, May 1, 2007; 30(5): 1289 - 1291. [Full Text] [PDF] |
||||
![]() |
A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. L. Ruel, B. Lamarche, J.-F. Mauger, K. O. Badellino, J. S. Cohn, M. Marcil, and P. Couture Effect of Fenofibrate on Plasma Lipoprotein Composition and Kinetics in Patients With Complete Hepatic Lipase Deficiency Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2600 - 2607. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Miida, O. Miyazaki, Y. Nakamura, S. Hirayama, O. Hanyu, I. Fukamachi, and M. Okada Analytical performance of a sandwich enzyme immunoassay for pre{beta}1-HDL in stabilized plasma J. Lipid Res., March 1, 2003; 44(3): 645 - 650. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Miida, O. Miyazaki, O. Hanyu, Y. Nakamura, S. Hirayama, I. Narita, F. Gejyo, I. Ei, K. Tasaki, Y. Kohda, et al. LCAT-Dependent Conversion of Pre{beta}1-HDL into {alpha}-Migrating HDL is Severely Delayed in Hemodialysis Patients J. Am. Soc. Nephrol., March 1, 2003; 14(3): 732 - 738. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |